Oncotarget

In The News - Press Releases


Oncotarget The value of lncRNA FENDRR and FOXF1 as a prognostic factor for survival


FOR IMMEDIATE RELEASE
2020-04-01

Oncotarget Volume 11, Issue 13 reported that the present study aimed to define the clinic pathological significance of the long-non-coding RNA FENDRR in lung adenocarcinomas.

Dr. Pedro P. Medina from the Department of Biochemistry and Molecular Biology I, as well as the Centre for Genomics and Oncological Research, PTS Granada, Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain said "Lung cancer is the most lethal cancer in most developed countries. Around half of the patients diagnosed with lung cancer die within one year of diagnosis and the 5-year survival rates are less than 18%"

"Lung cancer is the most lethal cancer in most developed countries. Around half of the patients diagnosed with lung cancer die within one year of diagnosis and the 5-year survival rates are less than 18%"

- Dr. Pedro P. Medina, Department of Biochemistry and Molecular Biology I & the Centre for Genomics and Oncological Research, Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica (GENYO)

Initially, FENDRR was first reported to be downregulated in gastric cancer compared with normal gastric cells and the low FENDRR expression was related to poor prognosis.

Recently, in lung cancer, a lnc RNA expression profiling identified to FENDRR as one of the lnc RNAs were differentially expressed between cancer and the adjacent normal tissues.

Additionally, also in lung cancer, FENDRR expression was associated with tumour migration and metastasis.

Figure 1: FENDRR and FOXF1 mRNAs are significant biomarkers of lung adenocarcinoma (LUAD). (A) FENDRR and FOXF1 expression was analyzed by qRT-PCR in 70 LUAD and 70 normal lung tissues. FENDRR and FOXF1 were significantly downregulated in lung adenocarcinomas versus their adjacent normal lung tissues. (B) The expression levels of FENDRR and FOXF1 was positive correlated in each other in lung tumor and adjacent normal lung tissues (Pearson's coefficient = 0.622, p<0.001).

In this study, the authors examined the expression levels of FENDRR and FOXF1 in lung cancer patients through qRT-PCR. They found FENDRR and FOXF1 expression was downregulated in lung adenocarcinomas compared to adjacent normal lung tissues and that FENDRR mRNA expression levels correlated positively with FOXF1 expression.

The Medina Research Team concluded in their Oncotarget Research Paper "this study identifies FENDRR and FOXF1 as novel potential tumour suppressor genes in lung cancer and that FENDRR acts by binding to unmethylated FOXF1 promoter. FENDRR and FOXF1 gene expression were predicted for overall survival, where patients with higher levels of FENDRR and FOXF1 expression had better prognosis. Thus, much more work is still required to determine the detailed mechanisms it functions in lung cancer and the potentiality of FENDRR and FOXF1 as therapeutic targets for lung cancer."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.22154

Full text - https://www.oncotarget.com/article/22154/text/

Correspondence to - Pedro P. Medina - pedromedina@ugr.es

Keywords - lncRNA, FENDRR, FOXF1, lung cancer, methylation

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105



Copyright © 2020 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC